Sweden: Jonebrant takes on acting CFO role at Isofol Medical as Albèrt departs

Isofol Medical, which is developing the drug candidate arfolitixorin with the aim of increasing the efficacy of current standard treatments for colorectal cancer and certain other tumour diseases, has appointed Roy Jonebrant as the new acting CFO. He succeeds Gustaf Albèrt who is leaving the CFO position as well as his vice CEO role. Jonebrant…

You must be a HMI Subscriber to view this content.

Subscribe Now »